POINT Biopharma Global Inc.
PNTDelisted Dec 27, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001811764
POINT Biopharma Global Inc. was delisted on Dec 27, 2023; its insiders filed their last Form 4 on Dec 27, 2023; 126 institutions reported holding it in 13F filings for Q3 2023, worth $411.0M in total; no superinvestor held it.
13F holders, Q4 2022
Institutional positions in POINT Biopharma Global Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 109
- +3 vs. Q3 2022
- Shares held
- 61.1M
- +257.4K (+0.4%) vs. Q3 2022
- Total value
- $445.5M
- −$24.9M (−5.3%) vs. Q3 2022
- New holders
- 20
- 48 more added
- Sold out
- 17
- 27 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PNT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 1 | $1.00K |
| Q3 2023 | 126 | $411.0M |
| Q2 2023 | 130 | $570.6M |
| Q1 2023 | 115 | $455.0M |
| Q4 2022 | 109 | $445.5M |
| Q3 2022 | 106 | $470.4M |
| Q2 2022 | 84 | $330.5M |
| Q1 2022 | 68 | $318.0M |
| Q4 2021 | 55 | $194.4M |
| Q3 2021 | 34 | $247.7M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding POINT Biopharma Global Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Great Point Partners LLC | 2,541,779 | $18.5M | 3.83% | −1,019,205−28.6% | Reduced |
| Suvretta Capital Management, LLC | 2,627,000 | $19.2M | 0.80% | +296,098+12.7% | Added |
| Point72 Asset Management, L.P. | 3,197,565 | $23.3M | 0.09% | −495,055−13.4% | Reduced |
| Citadel Advisors LLC | 3,251,580 | $23.7M | 0.03% | −428,417−11.6% | Reduced |
| State Street Corp | 4,286,257 | $31.2M | 0.00% | +1,277,089+42.4% | Added |
| Vanguard Group Inc | 4,391,923 | $32.0M | 0.00% | +516,601+13.3% | Added |
| PFM Health Sciences, LP | 4,633,802 | $33.8M | 1.43% | +118,586+2.6% | Added |
| BlackRock Inc. | 5,393,438 | $39.3M | 0.00% | −759,159−12.3% | Reduced |
| BVF Inc | 9,177,748 | $66.9M | 2.82% | +3,587,700+64.2% | Added |
| Fairmount Funds Management LLC | 0 | $0 | 0.00% | −2,833,950−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −1,322,508−100.0% | Sold out |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −1,000,000−100.0% | Sold out |
| Sio Capital Management, LLC | 0 | $0 | 0.00% | −544,545−100.0% | Sold out |
| Eversept Partners, LP | 0 | $0 | 0.00% | −410,052−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −346,171−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −131,260−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −115,102−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −69,078−100.0% | Sold out |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −43,836−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −16,615−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −14,962−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −13,600−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −10,282−100.0% | Sold out |
| Leonteq Securities AG | 0 | $0 | 0.00% | −9,000−100.0% | Sold out |
| Psagot Value Holdings Ltd. / (Israel) | 0 | $0 | 0.00% | −4,000−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −308−100.0% | Sold out |